128 related articles for article (PubMed ID: 11533092)
1. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.
Schrag D; Gelfand SE; Bach PB; Guillem J; Minsky BD; Begg CB
J Clin Oncol; 2001 Sep; 19(17):3712-8. PubMed ID: 11533092
[TBL] [Abstract][Full Text] [Related]
2. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population.
Dobie SA; Warren JL; Matthews B; Schwartz D; Baldwin LM; Billingsley K
Cancer; 2008 Feb; 112(4):789-99. PubMed ID: 18189291
[TBL] [Abstract][Full Text] [Related]
3. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study.
Neugut AI; Fleischauer AT; Sundararajan V; Mitra N; Heitjan DF; Jacobson JS; Grann VR
J Clin Oncol; 2002 Jun; 20(11):2643-50. PubMed ID: 12039925
[TBL] [Abstract][Full Text] [Related]
4. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.
Haynes AB; You YN; Hu CY; Eng C; Kopetz ES; Rodriguez-Bigas MA; Skibber JM; Cantor SB; Chang GJ
Cancer; 2014 Apr; 120(8):1162-70. PubMed ID: 24474245
[TBL] [Abstract][Full Text] [Related]
5. Residual treatment disparities after oncology referral for rectal cancer.
Morris AM; Billingsley KG; Hayanga AJ; Matthews B; Baldwin LM; Birkmeyer JD
J Natl Cancer Inst; 2008 May; 100(10):738-44. PubMed ID: 18477800
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.
Schrag D; Rifas-Shiman S; Saltz L; Bach PB; Begg CB
J Clin Oncol; 2002 Oct; 20(19):3999-4005. PubMed ID: 12351597
[TBL] [Abstract][Full Text] [Related]
8. Age and adjuvant chemotherapy use after surgery for stage III colon cancer.
Schrag D; Cramer LD; Bach PB; Begg CB
J Natl Cancer Inst; 2001 Jun; 93(11):850-7. PubMed ID: 11390534
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radiation therapy of rectal cancer.
Tepper JE
J Clin Oncol; 2001 Sep; 19(17):3709-11. PubMed ID: 11533091
[No Abstract] [Full Text] [Related]
10. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004.
Cree M; Tonita J; Turner D; Nugent Z; Alvi R; Barss R; King C; Winget M
Clin Colorectal Cancer; 2009 Jul; 8(3):141-5. PubMed ID: 19632928
[TBL] [Abstract][Full Text] [Related]
11. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States.
Baxter NN; Rothenberger DA; Morris AM; Bullard KM
Dis Colon Rectum; 2005 Jan; 48(1):9-15. PubMed ID: 15690651
[TBL] [Abstract][Full Text] [Related]
13. Surveillance, epidemiology, and end results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer.
Peng LC; Milsom J; Garrett K; Nandakumar G; Coplowitz S; Parashar B; Nori D; Clifford Chao KS; Wernicke AG
Cancer Epidemiol; 2014 Feb; 38(1):73-8. PubMed ID: 24491755
[TBL] [Abstract][Full Text] [Related]
14. Adherence to treatment guidelines in stage II/III rectal cancer in Alberta, Canada.
Eldin NS; Yasui Y; Scarfe A; Winget M
Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):e9-17. PubMed ID: 21802914
[TBL] [Abstract][Full Text] [Related]
15. A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer.
McGory ML; Zingmond DS; Sekeris E; Bastani R; Ko CY
Dis Colon Rectum; 2006 Mar; 49(3):319-29. PubMed ID: 16475031
[TBL] [Abstract][Full Text] [Related]
16. Less-than-standard treatment in rectal cancer patients: which patients are at risk?
Pisu M; Richardson LC; Kim YI; Krontiras H; Martin MY; Salas M; Pollack LA
J Natl Med Assoc; 2010 Mar; 102(3):190-8. PubMed ID: 20355348
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and treatment of patients receiving radiation for cancer of the rectum or sigmoid colon in the United States: results of the 1988-1989 Patterns of Care Study process survey.
Coia L; Wizenberg M; Hanlon A; Gunderson L; Haller D; Hoffman J; Kline R; Mohiuddin M; Russell A; Tepper J
J Clin Oncol; 1994 May; 12(5):954-9. PubMed ID: 8164047
[TBL] [Abstract][Full Text] [Related]
18. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
19. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
Thomschke D; Kyau-Ummen B; Halbfass HJ
Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
[TBL] [Abstract][Full Text] [Related]
20. Does patient age still affect receipt of adjuvant therapy for colorectal cancer in New South Wales, Australia?
Jorgensen ML; Young JM; Dobbins TA; Solomon MJ
J Geriatr Oncol; 2014 Jul; 5(3):323-30. PubMed ID: 24656735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
